ClinicalTrials.gg
CompletedNCT05872789Updated Dec 1, 2023

Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome

An interventional study of Diazepam 1% oral gel and Placebo in Burning Mouth Syndrome, sponsored by University of Catania. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by University of Catania · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled May 2020, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Burning mouth syndrome (BMS) is a syndrome characterized by burning and persistent oral pain, ranging from mild to intense, in the absence of organic disorders of the oral cavity and with a major impact on the quality of life of the sufferer. Although several etiological theories have been proposed to explain BMS, none has been universally accepted to date, and its origin remains unclear. Currently, several scientific evidences would suggest that underlying BMS would be alterations in certain neuropathic mechanisms.

The purpose of the study is to evaluate the efficacy of Diazepam 1% oral gel in the treatment of burning mouth syndrome.

Read the detailed description

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Diazepam 1% oral gel and determine the statistical significance of the outcome variables. 40 patients with BMS, in two groups:

  • case group with Diazepam 1% oral gel (Galenic formulation)
  • control group with placebo in oral gel formulation

Follow-up of 2 months

02

Conditions studied

  • Burning Mouth Syndrome

Browse trials for

03

In context

Burning Mouth Syndrome

47 studies on the registry are indexed under Burning Mouth Syndrome; 6 are open to participants now.

This study's enrollment of 40 is below the median of 48 across 38 interventional studies indexed under Burning Mouth Syndrome.

Browse Burning Mouth Syndrome studies →

Lead sponsor

University of Catania is the lead sponsor of 71 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome

Exclusion criteria

Exclusion Criteria:

    • clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with clinical signs that could justify the syndrome
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Diazepam 1% Oral gel

    Patients were treated with Diazepam 1% oral gel.

    Drug: Diazepam 1% oral gel

  • Placebo comparator
    Placebo

    Patients treated with a placebo gel control.

    Drug: Placebo

Interventions

  • DrugDiazepamStudies of DiazepamDiazepam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Diazepam 1% used with topic oral gel on tongue and palate twice daily.

  • DrugPlacebo

    Placebo oral gel used on tongue and palate twice daily.

06

What researchers measure

Primary outcomes

  1. Evolution of burning mouth

    Evolution of burning mouth symptoms change through questionnaries. The Visual Pain Analog Scale (VAS) will be used to assess pain, in which the value 0 indicates no pain and the value 100 maximum pain. The Oral Health Impact Profile Short Form (OHIP-14) will be used to assess the impact of oral problems on quality of life, in which the presence or absence of physical pain, functional limitation, psychological distress, physical, psychological and social disabilities, and handicap will be assessed.

    Time frame: 2 Months

07

Study locations

1 site
  • AOU Policlinico G. Rodolico
    Catania, 95124, Italy
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: 1 year

Access criteria: Pubmed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Sep 2023, 40 months.

Of 15 interventional studies with no phase under Burning Mouth Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 33. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
May 24, 2023
StartActual
May 2, 2020
Primary completionActual
Sep 12, 2023
CompletionActual
Oct 20, 2023
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05872789
Lead sponsor
University of Catania
Responsible party
Gaetano Isola (Principal researcher, University of Catania) — Principal investigator
First posted
May 24, 2023
Start date
May 2, 2020
Primary completion
Sep 12, 2023
Completion
Oct 20, 2023
Last update
Dec 1, 2023

Study contacts

Gaetano Isola
principal investigator · University of Catania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion